Retrophin Inc., a biopharmacy company founded by currently convicted pharmaceutical executive Martin Shkreli, is Travele Therapeutics Inc. The brand name has been changed as.
According to company officials, this new name is in favor of the Latin roots of truth and path. It breaks another link between the two hedge funds and the founder, Mr. Sukreri, who works in a securities fraud prison related to managing Retrofin. He will be released in 2023.
Widely despised for raising drug prices, including life-saving drugs used to treat HIV / AIDS and other immunocompromised patients, the name Retrofin stands for “Re (place) (dys) trophin.” I said there is.
In a document submitted by Mr. Sukurelli to several dystrophin officials, as he said, since it was resolved, he has caused and caused progressive muscle degeneration and weakness, a rare genetic disorder caused by it. After learning about a teenage boy who died of Duchenne muscular dystrophy, he was impressed by the absence of dystrophin, a protein involved in maintaining muscle integrity.
But the name is obsolete, said CEO Eric Duvet: the company that moved from New York to San Diego a few years ago is no longer working on treating DMD.
Founded by Martin Shkreli, Retrofin has changed its brand name to Travele Therapeutics.
Source link Founded by Martin Shkreli, Retrofin has changed its brand name to Travele Therapeutics.